Cannaponics, a medicinal cannabis manufacturer based in Western Australia, is preparing for a listing on the Australian Securities Exchange (ASX) later this year. The company aims to capitalize on the burgeoning legal cannabis market, projected to exceed $150 billion by 2030. Under the leadership of Rod Zakostelsky, Cannaponics plans to produce 15,000 tonnes of medicinal cannabis annually from its 165-acre facility located in Collie, in the South West region.
The company’s first harvest is expected in March or April 2024, as they move towards their initial public offering (IPO) in the latter half of the year. Zakostelsky emphasized that he has strategically diversified the company’s revenue streams to ensure its resilience against industry fluctuations. This includes the acquisition of the Club Hotel Collie, a hotel purchased for $550,000 to address regional housing challenges affecting staff recruitment and retention.
The hotel, which features 21 rooms, three bars, and a bottle shop, has become a vital asset for Cannaponics. Since the acquisition, it has nearly doubled its revenue to $6 million and is now catering to local mining workers. Plans are in place to expand the hotel by adding 48 additional rooms, which Zakostelsky estimates will increase annual revenue to $14 million.
Zakostelsky noted the importance of this diversification strategy: “We have diversified within the company to combat any future challenges that we may face within the industry.” He anticipates significant consolidation within the cannabis sector over the next 12 to 36 months but remains optimistic. Industry analyses predict that the global legal cannabis market will reach approximately $102 billion (USD) by 2030.
“We’re one of only half-a-dozen growers here in the country at the scale that we have, so for us it’s exciting to be part of that,” Zakostelsky added. To facilitate the upcoming IPO, Cannaponics has enlisted the services of Morgans as their lead manager and adviser.
This move to expand comes shortly after a pivotal change in the United States regarding cannabis classification. In a recent executive order, US President Donald Trump reclassified cannabis from a Schedule I drug to a Schedule III drug. This shift places cannabis alongside certain prescription painkillers, potentially opening new avenues for legal cannabis markets internationally.
As Cannaponics gears up for its ASX debut, the company not only aims to capture a share of a rapidly growing industry but also seeks to establish itself as a key player in the global medicinal cannabis landscape.
